Posts by: Jose Lopes

News

Use of an oral, delayed-release formulation of the ulcerative colitis treatment candidate PL-8177 led to targeted delivery to the lower gastrointestinal tract and was well-tolerated, according to top-line results ... Read more

February 15, 2019February 15, 2019

IBD Patients Have More DNA Damage in Lymphocytes, Less Vitamin B6, Study Reports

News

Patients with inflammatory bowel disease (IBD) have greater DNA damage in lymphocytes — a type of white blood cell — lower vitamin B6 and higher homocysteine levels than healthy ... Read more

February 1, 2019February 1, 2019

Specific Antibodies May Be Marker of Ulcerative Colitis in Young Patients, Study Suggests

News

A positive test for the proteinase 3-anti-neutrophil cytoplasmic antibodies (PR3-ANCA) may differentiate ulcerative colitis (UC) from Crohn’s disease (CD) in children and adolescents with inflammatory bowel disease (IBD), a study suggests. ... Read more

January 21, 2019January 21, 2019

Phase 3 Trials Test Upadacitinib for Moderately to Severely Active UC or CD

News

Two global Phase 3 trials are evaluating upadacitinib as a potential treatment for adults with moderately to severely active Crohn’s disease (CD) or ulcerative colitis (UC). The studies will ... Read more

December 19, 2018December 19, 2018

Protagonist Therapeutics Starts Phase 1 Trial of Potential Ulcerative Colitis Treatment PN-10943

News

Protagonist Therapeutics has begun dosing patients in a Phase 1 clinical trial of an oral ulcerative colitis (UC) treatment candidate known as PN-10943, the company announced in a press release. PN-10943 ... Read more

November 12, 2018November 12, 2018

FDA Approves Humira Biosimilar Hyrimoz for Treatment of IBD, Other Conditions

News

The U.S. Food and Drug Administration (FDA) approved Hyrimoz (adalimumab-adaz, by Sandoz), a biosimilar to AbbVie’s Humira (adalimumab) for the treatment of Crohn’s disease (CD) in adults and ulcerative colitis (UC). A ... Read more

September 26, 2018

Olorinab Eases Abdominal Pain Associated with Crohn’s Disease in Phase 2a Trial

News

Olorinab, an investigational compound being developed by Arena Pharmaceuticals, significantly reduced chronic abdominal pain in patients with Crohn’s disease, according to topline results from a Phase 2a clinical trial. The findings ... Read more

September 19, 2018September 19, 2018

Most IBD Specialists Support Continuing IBD Meds When Traveling to Areas With TB

News

About two-thirds of inflammatory bowel disease (IBD) specialists worldwide support continuing IBD medications when traveling to tuberculosis (TB)-endemic areas, while about half offer pre-travel advice. The data also show ... Read more

September 11, 2018September 11, 2018

Fecal Microbiota Transplant May Effectively Treat IBD, but More Research Needed, Review Study Says

News

Treating inflammatory bowel disease (IBD) with fecal microbiota transplant (FMT) shows potential, but longer clinical trials and more information on the best method of delivery, the risks, and the best ... Read more

July 25, 2018July 25, 2018

Vegetables, Whole Grains, Fruit, Beans Lower Risk of IBD, Study Suggests

News

Eating vegetables and whole grains reduces the risk of Crohn’s disease, while eating more fruit and beans/legumes lowers the risk of ulcerative colitis (UC), according to researchers in Canada. In ... Read more